search button

Cytotoxic T lymphocyte associated antigen 4 expression predicts poor prognosis in luminal B HER2-negative breast cancer

  • Authors:
    • Gaochen Lan
    • Jie Li
    • Qiaomei Wen
    • Lin Lin
    • Libin Chen
    • Liyu Chen
    • Xi Chen

  • View Affiliations

  • Published online on: February 7, 2018     https://doi.org/10.3892/ol.2018.7991
  • Pages: 5093-5097
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cytotoxic T lymphocyte associated antigen 4 (CTLA‑4) serves an important role in inhibiting anti‑tumor immune response in the majority of solid tumors. However, a limited number of studies reported the function of CTLA‑4 in luminal B HER2‑negative breast cancer. Immunohistochemistry was performed to evaluate the expression of tumor and interstitial CTLA‑4 in luminal B HER2‑negative breast cancer tissues. The percentage of patients with tumor and interstitial CTLA‑4+ was 41.2% (42/102) and 46.1% (47/102), respectively. There was a positive association between tumor CTLA‑4 expression and interstitial CTLA‑4 expression (P<0.05). The disease‑free survival (DFS) of the tumor CTLA‑4+ group was significantly shorter compared with patients with tumor CTLA‑4‑ (mean, 89.070 vs. 39.022 months; P<0.0001). Additionally, the DFS of interstitial CTLA‑4+ group was shorter compared with the interstitial CTLA‑4‑ group (mean, 85.526 vs. 46.574 months; P<0.0001). Tumor and interstitial CTLA‑4 expression may have prognostic predicting value in luminal B HER2‑negative breast cancer. The present study may provide the basis for the use of a CTLA‑4 blocker in patients with luminal B HER2‑negative breast cancer.
View Figures
View References

Related Articles

Journal Cover

April-2018
Volume 15 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Lan G, Li J, Wen Q, Lin L, Chen L, Chen L and Chen X: Cytotoxic T lymphocyte associated antigen 4 expression predicts poor prognosis in luminal B HER2-negative breast cancer. Oncol Lett 15: 5093-5097, 2018.
APA
Lan, G., Li, J., Wen, Q., Lin, L., Chen, L., Chen, L., & Chen, X. (2018). Cytotoxic T lymphocyte associated antigen 4 expression predicts poor prognosis in luminal B HER2-negative breast cancer. Oncology Letters, 15, 5093-5097. https://doi.org/10.3892/ol.2018.7991
MLA
Lan, G., Li, J., Wen, Q., Lin, L., Chen, L., Chen, L., Chen, X."Cytotoxic T lymphocyte associated antigen 4 expression predicts poor prognosis in luminal B HER2-negative breast cancer". Oncology Letters 15.4 (2018): 5093-5097.
Chicago
Lan, G., Li, J., Wen, Q., Lin, L., Chen, L., Chen, L., Chen, X."Cytotoxic T lymphocyte associated antigen 4 expression predicts poor prognosis in luminal B HER2-negative breast cancer". Oncology Letters 15, no. 4 (2018): 5093-5097. https://doi.org/10.3892/ol.2018.7991